TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment options for inoperable stages III and IV thymoma
Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: October 25, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Thymoma / Stage III and Stage IV Thymoma
Treatment options for patients with inoperable stage III and stage IV thymoma include:
Chemotherapy.
Chemotherapy followed by radiation therapy.
Chemotherapy followed by surgery (if operable) and radiation therapy.
The role of surgical debulking for patients with either stage III or stage IVA disease is controversial. Phase II data suggest that prolonged survival can be accomplished with chemotherapy and radiation therapy alone in many patients who present with locally advanced or even metastatic thymoma.[24] The value of surgery may be questioned if complete or, at the very least, near-complete extirpation cannot be accomplished.
Source links and citations
Evidence (treatment of stage III and IV inoperable thymoma):
An intergroup trial conducted in the United States reported a predicted 5-year OS rate of 52% in 26 patients who received the PAC chemotherapy regimen (cisplatin, doxorubicin, cyclophosphamide) followed by radiation therapy without surgery.[24]
Source links and citations
In a series of 30 patients with stage IV or locally progressive recurrent tumor after radiation therapy, the PAC regimen was given.[7][Level of evidence C3]
Source links and citations
In a series of 30 patients with stage IV or locally progressive recurrent tumor after radiation therapy, the PAC regimen was given.[7][Level of evidence C3]
A 50% response rate was achieved, including three complete responses.
In a series of 30 patients with stage IV or locally progressive recurrent tumor after radiation therapy, the PAC regimen was given.[7][Level of evidence C3]
The median duration of response was 12 months.
In a series of 30 patients with stage IV or locally progressive recurrent tumor after radiation therapy, the PAC regimen was given.[7][Level of evidence C3]
The 5-year survival rate was 32%.
The ADOC regimen (doxorubicin, cisplatin, vincristine, cyclophosphamide) was given to 37 patients.[8][Level of evidence C3]
Source links and citations
The ADOC regimen (doxorubicin, cisplatin, vincristine, cyclophosphamide) was given to 37 patients.[8][Level of evidence C3]
A 92% response rate (34 of 37 patients) was achieved, including complete responses in 43% of patients.
A study of combined chemotherapy with cisplatin and etoposide reported:[30][Level of evidence C3]
Source links and citations
A study of combined chemotherapy with cisplatin and etoposide reported:[30][Level of evidence C3]
A 56% response rate (9 of 16 patients) was achieved.
A study of combined chemotherapy with cisplatin and etoposide reported:[30][Level of evidence C3]
There was a median response duration of 3.4 years and a median survival of 4.3 years.
Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.[9][Level of evidence C3]
Source links and citations
Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.[9][Level of evidence C3]
Nine of 28 evaluable patients had partial responses (32%; 95% CI, 16%–52%).
Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.[9][Level of evidence C3]
The median follow-up was 43 months (range, 12.8–52.3).
Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.[9][Level of evidence C3]
The median duration of response was 11.9 months (range, <1–26).
Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.[9][Level of evidence C3]
The median OS was 31.6 months.
Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.[9][Level of evidence C3]
The 1-year survival rate was 89% and the 2-year survival rate was 70%, based on Kaplan-Meier estimates.
Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.[9][Level of evidence C3]
These results appear to be inferior to other combinations.
A phase II study evaluated the activity of a combination of carboplatin and paclitaxel in 46 patients with unresectable TETs, including 21 patients with unresectable thymoma.[10][Level of evidence C3]
Source links and citations
A phase II study evaluated the activity of a combination of carboplatin and paclitaxel in 46 patients with unresectable TETs, including 21 patients with unresectable thymoma.[10][Level of evidence C3]
Nine of 21 patients with thymoma had objective responses (42.9%; 90% CI, 24.5%–62.8%).
A phase II study evaluated the activity of a combination of carboplatin and paclitaxel in 46 patients with unresectable TETs, including 21 patients with unresectable thymoma.[10][Level of evidence C3]
The median duration of response in patients with thymoma was 16.9 months (95% CI, 3.1–22.0).
A phase II study evaluated the activity of a combination of carboplatin and paclitaxel in 46 patients with unresectable TETs, including 21 patients with unresectable thymoma.[10][Level of evidence C3]
The median progression-free survival for the thymoma cohort was 16.7 months (95% CI, 7.2–19.8); median OS was not reached after median follow-up of 59.4 months.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice